Companies · Biotechnology

Viratech Corp.

STOCKTON · Biotechnology

Diligence memoA one-page analyst read on Viratech Corp. — recommendation, valuation, rhythm, risks.
$261K
Total raised · real
2
Rounds
1.3×
Latest step-up
Top 95%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Fri Feb 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

Viratech Corp. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.51× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.
Dormant
  • Last raise 13.4 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Viratech Corp. is one of 4291 Biotechnology companies tracked from STOCKTON. By capital raised it ranks in the long tail (ahead of 6% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5M$5.0M$7.5M$10MPre-Seed · 2012-04-15 Raised $114K (real) Modeled valuation $6.3M (est)$114K$6.3MPre-Seed2012Pre-Seed · 2013-02-01 Raised $147K (real) Modeled valuation $8.1M (est)$147K$8.1MPre-Seed2013+$147KCumulative $261K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$114K · 2012
Pre-Seed extension$147K · 2013

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$8.1M
Base estimate est.
$78K
Conservative case
$92.0M
Upside case
$817K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $6.3M · 2012-04-152012Pre-Seed · modeled $8.1M · 2013-02-012013
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
13.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$327K/yr
Capital velocity
14.2 yr
On record since
2012
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$261K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.4× of median
This company$147K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$8.1M
Sector median$64.2M

Raised more than 6% of sector peers (real $). Modeled value above 15% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #116 of 131.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Truminim, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Direct Spinal Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Imanis Life Sciences, LLC · Pre-Seed Raised $1.0M · modeled $55.2M (est)Universal Biosensors Inc · Pre-Seed Raised $985K · modeled $54.4M (est)One World Lab, Inc. · Pre-Seed Raised $981K · modeled $54.2M (est)Micropharma Ltd · Pre-Seed Raised $851K · modeled $47.0M (est)ConverGene LLC · Pre-Seed Raised $850K · modeled $46.9M (est)CVUS Ventures, LP · Pre-Seed Raised $850K · modeled $46.9M (est)Symbiotic Health, Inc. · Pre-Seed Raised $850K · modeled $46.9M (est)EternoGen Aesthetics, LLC · Pre-Seed Raised $939K · modeled $46.3M (est)Genomics USA, Inc. · Pre-Seed Raised $837K · modeled $46.2M (est)Immunetics, Inc. · Pre-Seed Raised $1.5M · modeled $46.1M (est)Viratech Corp. (this company) Raised $261K · modeled $8.1M (est)Viratech Corp.
CompanyStageRaised · realValue · estvs peer med.
Truminim, LLCPre-Seed$1.0M$55.2M3.48×
Direct Spinal Therapeutics, Inc.Pre-Seed$1.0M$55.2M3.48×
Imanis Life Sciences, LLCPre-Seed$1.0M$55.2M3.48×
Universal Biosensors IncPre-Seed$985K$54.4M3.43×
One World Lab, Inc.Pre-Seed$981K$54.2M3.42×
Micropharma LtdPre-Seed$851K$47.0M2.96×
ConverGene LLCPre-Seed$850K$46.9M2.96×
CVUS Ventures, LPPre-Seed$850K$46.9M2.96×
Symbiotic Health, Inc.Pre-Seed$850K$46.9M2.96×
EternoGen Aesthetics, LLCPre-Seed$939K$46.3M2.92×
Genomics USA, Inc.Pre-Seed$837K$46.2M2.92×
Immunetics, Inc.Pre-Seed$1.5M$46.1M2.91×
Viratech Corp. this companyPre-Seed$261K$8.1M0.51×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$114K2012-04-15$634K$6.3M90%
Pre-Seed$147K2013-02-01$817K$8.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$114K2012-04-15
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$147K2013-02-01
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
Intelligence
2013 ~Q4
Modeled next raise · ~10mo cadence
$189K
Modeled next size est.range $147K$303K
1.3×
Last step-up
$327K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Kevin Buckman2012-04
Registry & provenance

Viratech Corp. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1130781
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Spartan Bioscience Inc.BiotechnologyPre-Seed$260K$6.1Msame sector · same stage
Diag-Nose Medical Pty LtdBiotechnologyPre-Seed$263K$10.5Msame sector · same stage
Early Stage Cancer Detection, Inc.BiotechnologyPre-Seed$257K$7.4Msame sector · same stage
Atlee Biotech, Inc.BiotechnologyPre-Seed$250K$5.5Msame sector · same stage
Globavir Biosciences Inc.BiotechnologyPre-Seed$250K$8.3Msame sector · same stage
VCENNA, IncBiotechnologyPre-Seed$250K$5.3Msame sector · same stage
Zumatek, Inc.BiotechnologyPre-Seed$250K$8.3Msame sector · same stage
BioVaxys Technology Corp.BiotechnologyPre-Seed$249K$7.2Msame sector · same stage
Frequently asked
How much funding has Viratech Corp. raised?
Viratech Corp. has raised approximately $261K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Viratech Corp.'s estimated valuation?
Provath's modeled valuation for Viratech Corp. is approximately $8.1M (modeled range $78K–$92.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Viratech Corp. at?
Viratech Corp.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Fri Feb 01.
What does Viratech Corp. do and where is it based?
Viratech Corp. operates in the Biotechnology sector, based in STOCKTON.
Explore related

See where Viratech Corp. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Viratech Corp., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.